STOCK TITAN

ASLAN Pharmaceuticals Limited - ASLN STOCK NEWS

Welcome to our dedicated page for ASLAN Pharmaceuticals news (Ticker: ASLN), a resource for investors and traders seeking the latest updates and insights on ASLAN Pharmaceuticals stock.

ASLAN Pharmaceuticals Limited (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company dedicated to developing innovative treatments that transform the lives of patients. Headquartered in Singapore with offices in Taiwan and China, ASLAN is tackling high-prevalence diseases in Asia and orphan indications in the United States and Europe.

ASLAN's strategic portfolio includes four product candidates targeting validated growth pathways, novel immune checkpoints, and cancer metabolic pathways. Their flagship projects are eblasakimab, a first-in-class antibody targeting the IL-13 receptor for moderate-to-severe atopic dermatitis (AD), and farudodstat, an oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) for alopecia areata (AA).

In recent developments, eblasakimab has shown promising results in a Phase 2b, dose-ranging study, achieving significant improvements in AD patients. Concurrently, farudodstat is progressing through a Phase 2a, proof-of-concept trial with interim results expected soon.

ASLAN actively collaborates with industry leaders such as Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL to bolster their research and development efforts. The company's strategic alliances aim to leverage combined expertise for enhanced therapeutic outcomes.

On March 12, 2024, ASLAN announced a definitive agreement to sell 5,000,000 American Depositary Shares (ADSs) at $1.00 per ADS in a direct offering, with warrants issued in a concurrent private placement. The proceeds will fund ongoing R&D activities and general corporate purposes.

Despite financial challenges, including a reported deficit of $13.3 million in stockholders’ equity for 2023, ASLAN is committed to regaining compliance with Nasdaq listing requirements. This determination is underscored by their continuous efforts to advance their clinical pipeline and explore new research collaborations, such as their recent agreement with Zenyaku Kogyo Co., Ltd.

ASLAN's proactive approach, supported by a solid management team with deep global and regional expertise, aims to generate significant clinical advances and commercial opportunities. For more information, visit the ASLAN website or follow them on LinkedIn.

Rhea-AI Summary

ASLAN Pharmaceuticals has announced that its sole operating subsidiary, ASLAN Pharmaceuticals Pte (ASLAN SG), has filed for voluntary liquidation. This decision follows a comprehensive review of strategic alternatives by the company's board. Quantuma (Singapore) Pte has been appointed as the official liquidator to manage the winding up of ASLAN SG's affairs, including seeking potential alternatives for its development programs, eblasakimab and farudodstat.

All employees of ASLAN SG and ASLAN Pharmaceuticals (USA) Inc. have been terminated. The parent company, ASLAN Pharmaceuticals, will also apply for liquidation under Cayman law. Additionally, ASLAN has received a staff delisting determination from Nasdaq due to failure to meet continued listing requirements. The company expects its American Depository Shares (ADSs) to be suspended from trading and moved to the over-the-counter market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.95%
Tags
none
-
Rhea-AI Summary

ASLAN Pharmaceuticals (Nasdaq: ASLN) has announced that it received a delisting determination from Nasdaq on July 9, 2024, due to non-compliance with the $1.00 bid price and $2.5 million stockholders' equity requirements. The company's board has decided not to appeal this decision. ASLAN had previously been notified of these compliance issues and was given time to address them. On July 3, 2024, the company implemented a ratio change for its American Depositary Shares (ADSs), resulting in a closing price above $1.00. However, as of the press release date, the bid price had only closed above $1.00 for five consecutive business days, falling short of the required ten to twenty-day compliance period.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.88%
Tags
none
-
Rhea-AI Summary

ASLAN Pharmaceuticals has announced a change in the ratio of its American Depositary Shares (ADSs) to ordinary shares. Effective July 3, 2024, the ratio will shift from 1 ADS representing 25 ordinary shares to 1 ADS representing 200 ordinary shares. This will effectively result in a one-for-eight reverse ADS split. Existing ADS holders do not need to take action, as the change will occur automatically. The trading price of ADSs is expected to increase proportionally, but there is no guarantee it will be eight times the pre-change price. The ADSs will continue trading under the symbol 'ASLN' on Nasdaq.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.17%
Tags
none
Rhea-AI Summary

ASLAN Pharmaceuticals presented late-breaking translational data on eblasakimab at the American Thoracic Society International Conference. The study, comparing eblasakimab to dupilumab in human tissue models of COPD, showed that eblasakimab significantly improved airway function and bronchodilation.

Eblasakimab effectively blocked Type-2 inflammation in lung tissue, outperforming dupilumab in reducing airway constriction and enhancing dilation. The findings suggest eblasakimab as a promising therapeutic option for COPD and other Type-2 driven lung conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
none
-
Rhea-AI Summary

ASLAN Pharmaceuticals reported positive interim data from the TREK-DX study of eblasakimab, showing unprecedented efficacy in atopic dermatitis patients. Additionally, the company announced favorable patent opinions and collaborations with Zenyaku. Financially, ASLAN saw a decrease in cash used for operations and research expenses, resulting in a lower net loss for Q1 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
-
Rhea-AI Summary

ASLAN Pharmaceuticals will present new positive data from an interim analysis of the Phase 2 TREK-DX study of Eblasakimab in dupilumab-experienced atopic dermatitis patients during a virtual KOL event. The data support the effectiveness of Eblasakimab in patients with an inadequate response to dupilumab, showing significant improvements in EASI and vIGA scores. The presentation will include secondary endpoints, rapid onset of effect, low discontinuation rates, and promising outcomes for patients with prior inadequate response to dupilumab. The event will feature discussions with key opinion leaders on the emerging market for alternative treatments in AD patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
conferences clinical trial
Rhea-AI Summary

ASLAN Pharmaceuticals has announced an expanded research collaboration with Zenyaku to investigate the differentiation of eblasakimab versus other biologics for atopic dermatitis. The partnership will deepen the understanding of why some patients respond better to eblasakimab over dupilumab. The new agreement builds on their existing commercial partnership in Japan. The research aims to explore the receptor biology and kinetics to understand eblasakimab's unique mechanism of action.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
none
-
Rhea-AI Summary

ASLAN Pharmaceuticals, a clinical-stage biopharmaceutical company, will host a virtual Key Opinion Leader (KOL) Event discussing treatment options for atopic dermatitis patients with an inadequate response to Dupilumab on May 7, 2024. The event will feature leading medical professionals and present new data from the interim analysis of the TREK-DX study, showcasing positive results for Eblasakimab, a potential first-in-class biologic candidate.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
conferences
-
Rhea-AI Summary
ASLAN Pharmaceuticals announced that an abstract on eblasakimab in Chronic Obstructive Pulmonary Disease (COPD) has been accepted for presentation at the American Thoracic Society International Conference 2024. The poster will discuss how Eblasakimab alleviates bronchial airway constriction in COPD patients. The presentation will be made by Dr. Ferda Cevikbas, Head of Translational Science at ASLAN Pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
Rhea-AI Summary
ASLAN Pharmaceuticals announces positive interim results from the Phase 2 study of Eblasakimab in Dupilumab-experienced Atopic Dermatitis patients. The study shows unprecedented efficacy data with significant improvements in EASI scores, vIGA scores, and itch relief compared to placebo. Eblasakimab demonstrated high effectiveness in patients previously treated with dupilumab, indicating its potential as a new therapy for this patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.13%
Tags

FAQ

What is ASLAN Pharmaceuticals' focus?

ASLAN Pharmaceuticals focuses on developing innovative treatments for immunology and oncology, targeting diseases prevalent in Asia and rare indications in the US and Europe.

What are ASLAN Pharmaceuticals' main products?

ASLAN is developing eblasakimab for atopic dermatitis and farudodstat for alopecia areata, both showing promising results in clinical trials.

Where is ASLAN Pharmaceuticals headquartered?

ASLAN Pharmaceuticals is headquartered in Singapore, with additional offices in Taiwan and China.

Who are ASLAN Pharmaceuticals’ partners?

ASLAN collaborates with Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL to enhance their research and development capabilities.

What recent financial activities has ASLAN Pharmaceuticals undertaken?

ASLAN recently announced a direct offering of 5,000,000 ADSs at $1.00 per ADS to fund research and development activities.

What clinical advancements has ASLAN Pharmaceuticals made recently?

ASLAN announced positive topline results from the Phase 2b study of eblasakimab in atopic dermatitis and interim results from the Phase 2a study of farudodstat in alopecia areata.

How is ASLAN Pharmaceuticals addressing its financial challenges?

ASLAN is working towards regaining compliance with Nasdaq listing requirements and is actively seeking financial and strategic solutions to bolster their equity.

What is the purpose of ASLAN Pharmaceuticals’ recent collaboration with Zenyaku Kogyo?

The collaboration aims to explore the differentiation of eblasakimab’s mechanism of action versus other biologic therapies for atopic dermatitis.

What is eblasakimab?

Eblasakimab is a first-in-class antibody targeting the IL-13 receptor, developed by ASLAN to treat moderate-to-severe atopic dermatitis.

What are the potential benefits of farudodstat?

Farudodstat is a potent oral inhibitor targeting the enzyme DHODH, showing potential as a first-in-class treatment for alopecia areata.

ASLAN Pharmaceuticals Limited

Nasdaq:ASLN

ASLN Rankings

ASLN Stock Data

1.70M
565.67M
0.14%
13.21%
1.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
190 Elgin Avenue